Cost-effectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in Chinese
Authors:
- 24 January 2008
- journal article
- general essays
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 24 (1) , 87-95
Abstract
Objectives: The aim of this study was to evaluate the costs and effectiveness associated with no screening, Helicobacter pylori serology screening, and the 13C-urea breath test (UBT) for gastric cancer in the Chinese population. Methods: A Markov model simulation was carried out in Singaporean Chinese at 40 years of age (n = 478,500) from the perspective of public healthcare providers. The main outcome measures were costs, number of gastric cancer cases prevented, life-years saved, quality-adjusted life-years (QALYs) gained from the screening age to death, and incremental cost-effectiveness ratios (ICERs), which were compared among the three strategies. The uncertainty surrounding ICERs was addressed by scenario analyses and probabilistic sensitivity analysis using Monte Carlo simulation. Results: The ICER of serology screening versus no screening was $25,881 per QALY gained (95 percent confidence interval (95 percent CI), $5,700 to $120,000). The ICER of UBT versus no screening was $53,602 per QALY gained (95 percent CI, $16,000 to $230,000). ICER of UBT versus serology screening was $470,000 per QALY gained, for which almost all random samples of the ICERs distributed above $50,000 per QALY. Conclusions: It cannot be confidently concluded that either H pylori screening was a cost-effective strategy compared with no screening in all Chinese at the age of 40 years. Nevertheless, serology screening has demonstrated much more potential to be a cost-effective strategy, especially in the population with higher gastric cancer prevalence.Keywords
This publication has 26 references indexed in Scilit:
- Systematic review: Helicobacter pylori eradication for the prevention of gastric cancerAlimentary Pharmacology & Therapeutics, 2006
- Endoscopic Screening for Gastric CancerClinical Gastroenterology and Hepatology, 2006
- Racial differences in Helicobacter pylori, serum pepsinogen and gastric cancer incidence in an urban Asian populationJournal of Gastroenterology and Hepatology, 2005
- Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary studyDigestive and Liver Disease, 2003
- An Introduction to Markov Modelling for Economic EvaluationPharmacoEconomics, 1998
- H pylori and gastric cancerThe Lancet, 1994
- Markov Models in Medical Decision MakingMedical Decision Making, 1993
- An international association between Helicobacter pylori infection and gastric cancerThe Lancet, 1993
- Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation.BMJ, 1991
- Comparison of 5- and 10-year survival rates in operated gastric cancer patientsLangenbeck's Archives of Surgery, 1982